Drug Trial Radar · NCT05973149
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Aug 31, 2025
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer
Conditions
- Prostate Cancer
Interventions
QLH12016Drug
according to the scheme description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A: Incidence of Dose Limiting ToxicitiesTime frame: 28 Days
- Arm A:Maximum Tolerated DoseTime frame: 28 Days
- Arm A:Recommended Phase 2 DoseTime frame: 28 Days
- Arm A:AETime frame: 20 weeks
- Arm A:SAETime frame: 20 weeks
- Arm B-D:PSA Response RateTime frame: 20 weeks
- Arm B-D:Objective Response RateTime frame: 20 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Urology, Peking University First Hospital
Beijing, Beijign, China
Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.